Saturday, 24 October 2015

NeuroSpeak: finally the EMA gives update on DMF

Finally the EMA has an opinion on DMF-related lymphopaenia. Thank you. #MSBlog #NeuroSpeak

"The following is the provisional update from the EMA regarding dimethyl fumarate or DMF (Tecfidera)."


Having reviewed the available information on the risk of PML, EMA has recommended the following to minimise this risk with Tecfidera:

  • Prior to initiating treatment with Tecfidera, a complete blood count including a lymphocyte count should be performed and a baseline MRI scan should be available (usually within 3 months) as a reference. After starting therapy, complete blood counts including lymphocytes should be performed every 3 months.

"For how long? Biogen's data states that if you don't develop lymphopaenia in the first year you are unlikely to do so; why then do we need to continue 3-monthly monitoring indefinitely?"

  • If during treatment with Tecfidera the lymphocyte count drops below 0.5x109/L for more than 6 months, the benefit-risk of continued treatment with Tecfidera should be re-considered in the context of other therapeutic options available. Clinical factors and evaluation of any laboratory and imaging investigations could be included as part of this re-consideration. If Tecfidera is discontinued, the lymphocyte count should be closely monitored until recovery.

"I don't agree with this cut-off. Why? There have been two cases of PML in patients with psoriasis on fumarates who developed PML with a lymphocyte count above 0.5, but below 0.8. This is why I will stick to 0.8 as my cut-off. However, I suspect JCV-serostatus may play a role here. If you are JCV-ve the risk of PML will be low."

  • PML can only occur in the presence of JC virus infection. If an anti-JC virus antibody test is done, it should be considered that the influence of lymphopenia on the accuracy of such tests has not been studied in patients treated with Tecfidera. Doctors should also note that a negative antibody test (in the presence of normal lymphocyte counts) does not preclude the possibility of subsequent JC virus infection.

"This is stating the obvious."

  • During treatment with Tecfidera, the need for further MRI scans should be considered in accordance with national and local recommendations. MRI imaging may be considered as part of increased vigilance in patients considered at increased risk of PML. In case of clinical suspicion of PML, MRI should be performed immediately for diagnostic purposes.

"No comment!"

  • If therapy is continued in patients with severe prolonged lymphopenia, these patients should be considered at increased risk for PML and should be monitored closely for signs and symptoms of new neurological dysfunction (e.g. motor dysfunction, cognitive or psychiatric symptoms).

"No comment!"

  • In case PML is suspected, treatment with Tecfidera should be withheld immediately and further evaluations performed.

"No advice on treating PML? This may be an indication for a donor lymphocyte transplant from a MHC identical donor who is JCV+ve. What these patients need is a robust and quick cytotoxic CD8+ lymphocyte response against JCV infected cells so that they can recover from their PML. The latter is an experiment waiting to happen."

  • No studies have been performed evaluating the efficacy and safety of Tecfidera when switching patients from other disease-modifying therapies to Tecfidera. The contribution of prior immunosuppressive therapy to the development of PML in patients treated with Tecfidera is unknown. When switching patients from other disease-modifying therapy to Tecfidera, the half-life and mode of action of the other therapy must be considered in order to avoid an additive immune effect whilst at the same time reducing the risk of disease reactivation.

"Good point. As I have said before if you switch from other immunosuppressive drugs you are likely to take some risk with you. PML is a complex process with the virus needing to mutate and acquire several mutations. The latter are unlikely to unwind on switching therapies."

7 comments:

  1. Re "For how long? Biogen's data states that if you don't develop lymphopaenia in the first year you are unlikely to do so; why then do we need to continue 3-monthly monitoring indefinitely?"

    There are many reasons why our lymphocyte count change and changes can happen fairly quickly.
    The most recent case of PML of an MSer on Tecfidera I am sure they developed lymphopaenia within six months of taking Tecfidera. They were on Rebif before Tecfidera.
    My hosptial informed me after 12 months on Tecfidera my blood tests will be yearly. A yearly blood test on Tecfidera I do not feel is suitable, it needs to be more frequent.


    ReplyDelete
  2. After having low lymphocytes on Tecfidera and being JCV positive, is Copaxone or Interferons my only safe option?

    ReplyDelete
  3. How long does it take to go back from lymphopenia to normal after stopping Tecfidera? When is the PML risk from Tecfidera gone?

    ReplyDelete
  4. Fumaderm and Psorinovo are prescribed for short time in comparison with Tecfidera that is long life treatment. Will be expected more PML cases with Tecfidera than Fumaderm and Psorinovo?

    ReplyDelete
    Replies
    1. We will have to see how real life treatment plays out.

      Delete
  5. continued thanks for this blog.
    How strong are these 'recommendations' for the UK?
    I have only ever had one MRI (non contrast) and nonMRI of my spine during relapse. Should We be asking about baseline MRIs? Don't want to seem pushy. if lymphocytes below 1 should we be asking for JCV testing?
    Sorry that may be a bit close to giving individual advice but am asking it on a quite general level as want to keep informed and involved.

    ReplyDelete
  6. Good point Sue, these are recommendations only and Biogen will hopefully respond to this soon. In the meantime I'm sure individual centres will be advising on this. Firstly, JCV testing before starting isn't routinely performed, secondly the three month baseline MRI is arbitrary - why not 6 months or an year (there shouldn't be a reason for increased risk on switching from CRAB drugs, or de novo PML in treatment naïve), thirdly, we still don't understand the contribution of lymphopenia to the overall PML risk as the case numbers have been so far been small and we're simply extrapolating from this.

    What we should be focusing on are ways of treating it as well...

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.